Results 121 to 130 of about 238,162 (269)

Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages.
Chun Li   +17 more
wiley   +1 more source

Additional file 2: Table S2. of Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimerâ s disease model

open access: yes, 2017
Statement on sample size and statistical measures. (PDF 1351 kb)
Liu, Yi-Ling   +5 more
openaire   +1 more source

The Association of Amyloid‐β and Tau With Synaptic Dysfunction in Alzheimer's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To clarify the relative contributions of amyloid and tau to synaptic dysfunction in Alzheimer's disease (AD). Methods We included 109 cognitively unimpaired and impaired individuals from the Geneva Memory Center with available CSF synaptic biomarkers (neurogranin, SNAP‐25, GAP‐43). Participants were stratified according to amyloid (A)
Fausto Roveta   +11 more
wiley   +1 more source

Additional file 1: Table S1. of Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimerâ s disease with cerebrovascular disease

open access: yes, 2017
Detail of the human postmortem brain tissues analyzed. (DOC 34Â kb)
Gallart-Palau, Xavier   +4 more
openaire   +1 more source

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham   +7 more
wiley   +1 more source

Additional file 1: Figure S1. of Genome-wide alteration of 5-hydroxymenthylcytosine in a mouse model of Alzheimerâ s disease

open access: yes, 2016
A representative image of methylene blue staining showing the equal spotting of DNA in the membrane. Figure S2 5hmC chromosome-wide densities showing the distribution profiling on chromosomes. A depletion is observed on chr-X relative to autosomes. Figure S3 Representative IGV images show the decrease of 5hmC in some genomic regions of genes identified
Shu, Liqi   +10 more
openaire   +1 more source

Associations Between Biomarkers of Alzheimer's Disease and Sleep in Cognitively Unimpaired Older Adults

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Sleep disturbances have been implicated as a risk factor for developing Alzheimer's disease (AD), but evidence linking plasma AD biomarkers to sleep in cognitively unimpaired individuals remains limited. The present study examined associations between evening, morning, and overnight changes in plasma AD biomarkers and measures of ...
Cornelia Sauter   +5 more
wiley   +1 more source

The YTHDF proteins modulate Alzheimer’s disease-associated brain gene signatures

open access: yesMolecular Neurodegeneration
Gene signatures of Alzheimer’s disease (AD) brains reflect the output of a complex interplay of genetic, epigenetic, epi-transcriptomic, and post-transcriptional regulations.
Shinya Tasaki   +21 more
doaj   +1 more source

Additional file 2: of PU.1 regulates Alzheimerâ s disease-associated genes in primary human microglia

open access: yes, 2018
Table S2. List of antibodies and reagents for ICC and IHC (DOCX 17 kb)
Rustenhoven, Justin   +16 more
openaire   +1 more source

Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy